Evaluation of antibodies to oxidized low-density lipoprotein in children with obesity of different degrees

Introduction. The interest in the study of anti-oxidized low-density lipoproteins (anti-oxLDL) is due to their association with the development and progression of atherosclerosis and metabolic syndrome. Purpose of the study. To study the level of antibodies of oxidized low-density lipoproteins (anti-oxLDL) in serum in obese children. Materials and Methods. 76 children aged 5 to 17 years participated in the study. A standard objective and laboratory examination was performed, including physical and sexual development, lipidogram and anti-oxLDL levels. To assess anthropometric data, the standard deviation coefficient was calculated using the Auxology application. The parameters of fat metabolism were determined according to the data of blood biochemical analysis. The content of anti-oxLDL was determined by immuno-enzymatic analysis using test kits “Biomedica”. Results. According to the results of the examination the patients were divided into three groups: group 1 included 36 children with constitutional-exogenous obesity and increased level of anti-oxLDL, group 2-30 patients with constitutional-exogenous obesity and normal level of anti-oxLDL, group 3-10 healthy children. The level of antibodies to oxidized low density lipoproteins (oxLDL) in obese children is 11.6 times higher compared to healthy children. The antibody titer in prepubertal children is 2206 [1809;2603] IU/mL, and in adolescents it is 1505.5 [1109;1902] IU/mL. The highest values of anti-oxLDL levels were observed in patients with 1st degree obesity 2623 [2245;3001] IU/mL and 3rd degree obesity 2914.5 [2678;3151] IU/mL. Conclusion. High of anti-oxLDL levels were found in pre-pubertal children with obesity, especially in 1st and 3rd degree obesity. In obese children, the level of anti-oxLDL has a direct correlation with the duration of the underlying disease and the increase in low-density lipoprotein (LDL) levels. Further studies are needed on the role of anti-OCOLDL as an early predictor of atherosclerosis in clidren with obesity.

obesity, low-density lipoproteins, antibodies to oxidized low-density lipoproteins, children

1. Milner E. B., Evdokimova N. V., Novikova V. P. et al. Cardiovascular risks in obese adolescents. Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2022; 17(5): 83-89. (In Russ.) doi: 10.20953/1817-7646-2022-5-83-89.@@ Мильнер Е. Б., Евдокимова Н. В., Новикова В. П. и соавт. Кардиоваскулярные риски подросткового ожирения. Вопросы практической педиатрии. 2022; 17(5): 83-89. doi: 10.20953/1817-7646-2022-5-83-89.

2. Martseva E. M., Evdokimova N. V., Prokopyeva N. E. The role of homocystein in the pathogenesis of arterial hypertension in obesity and comorbid diseases. Children’s medicine of the North-West (St. Petersburg). 2023;11(4):39-46. (in Russ.) doi: 10.56871/CmN-W.2023.18.64.004.@@ Марцева Е. М., Евдокимова Н. В., Прокопьева Н. Э. Роль гомоцистеина в патогенезе артериальной гипертензии при ожирении и коморбидных заболеваниях. Детская медицина Северо-Запада. 2023;11(4):39-46. doi: 10.56871/CmN-W.2023.18.64.004.

3. Razgonyaeva A. E., Evdokimova N. V. Dyslipidemia is a risk factor for arterial hypertension in obesity in children. University therapeutic journal (St. Petersburg). 2024;6(1):49-57. (in Russ.) doi: 10.56871/UTJ.2024.99.98.004.@@ Разгоняева А. Е., Евдокимова Н. В. Дислипидемия как фактор риска артериальной гипертензии при ожирении у детей. Университетский терапевтический вестник. 2024;6(1):49-57. doi: 10.56871/UTJ.2024.99.98.004.

4. Shogenova M. H., Zhetisheva R. A., Karpov A. M. et al. The role of oxidized low-density lipoproteins and antibodies against oxidized low-density lipoproteins in the immune and inflammatory process in atherosclerosis. Atherosclerosis and dyslipidemias. 2015. (in Russ.) Available at: https://cyberleninka.ru/article/n/rol-okislennyh-lipoproteinov-nizkoy-plotnosti-i-antitel-k-nim-v-immunno-vospalitelnom-protsesse-pri-ateroskleroze. Accessed: 30.06.2024@@ Шогенова М. Х., Жетишева Р. А., Карпов А. М. и соавт. Роль окисленных липопротеинов низкой плотности и антител к ним в иммунно-воспалительном процессе при атеросклерозе. Атеросклероз и дислипидемии. 2015. № 2. URL: https://cyberleninka.ru/article/n/rol-okislennyh-lipoproteinov-nizkoy-plotnosti-i-antitel-k-nim-v-immunno-vospalitelnom-protsesse-pri-ateroskleroze (дата обращения: 30.06.2024).

5. Fefelova E. V., Khyshiktuev B. S., Maksimenya M. V. et al. Content of oxidated low density lipoproteins and antibodies to them in healthy persons and patients with cardiovascular pathology. Far Eastern Medical Journal. 2013. № 1. (in Russ.) Available at: https://cyberleninka.ru/article/n/soderzhanie-okislennyh-lipoproteinov-nizkoy-plotnosti-i-antitel-k-nim-u-zdorovyh-lits-i-u-patsientov-s-serdechno-sosudistoy-patologiey. Accessed: 30.06.2024.@@ Фефелова Е. В., Хышиктуев Б. С., Максименя М. В. и соавт. Содержание окисленных липопротеинов низкой плотности и антител к ним у здоровых лиц и у пациентов с сердечно-сосудистой патологией. Дальневосточный медицинский журнал. 2013. № 1. URL: https://cyberleninka.ru/article/n/soderzhanie-okislennyh-lipoproteinov-nizkoy-plotnosti-i-antitel-k-nim-u-zdorovyh-lits-i-u-patsientov-s-serdechno-sosudistoy-patologiey (дата обращения: 30.06.2024).

6. Berns S., Shmidt E., Khomiakova T. Role of oxidative lipoprotein metabolism in patients with ischemic heart disease. Medicine in Kuzbass. 2016. № 1. (in Russ.) Available at: https://cyberleninka.ru/article/n/okislitelnyy-metabolizm-lipoproteinov-u-bolnyh-ishemicheskoy-boleznyu-serdtsa. Accessed: 30.06.2024.@@ Бернс С. А., Шмидт Е. А., Хомякова Т. А. Окислительный метаболизм липопротеинов у больных ишемической болезнью сердца. Мв К. 2016. № 1. URL: https://cyberleninka.ru/article/n/okislitelnyy-metabolizm-lipoproteinov-u-bolnyh-ishemicheskoy-boleznyu-serdtsa (дата обращения: 30.06.2024).

7. Peterkova V. A., Bezlepkina O. B., Bolotova N. V. et al. Clinical guidelines «Obesity in children». Problems of Endocrinology. 2021;67(5):67-83. (In Russ.) doi: 10.14341/probl12802.@@ Петеркова В. А., Безлепкина О. Б., Болотова Н. В. и соавт. Клинические рекомендации «Ожирение у детей». Проблемы эндокринологии. 2021;67(5):67-83. doi: 10.14341/probl12802.

8. Yasunobu Y., Hayashi K., Shingu T. et al. The significance of the circulating levels of autoantibodies to oxidized low density lipoprotein (Ox-LDL) in the patients who have ischemic heart disease. Atherosclerosis. 1997;134(1-2): 304.

9. Babakr A. T., Elsheikh O. M., Almarzouki A. A. et al. Relationship between oxidized low-density lipoprotein antibodies and obesity in different glycemic situations. Diabetes Metab Syndr Obes. 2014 Oct 24;7:513-20. doi: 10.2147/DMSO.S70904.

10. Shoenfeld Y., Wu R., Dearing L. D. el al. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation. 2004 Oct 26;110(17):2552-8. doi: 10.1161/01.CIR.0000143225.07377.EA.

11. Wirestam L., Jönsson F., Enocsson H. et al. Limited Association between Antibodies to Oxidized Low-Density Lipoprotein and Vascular Affection in Patients with Established Systemic Lupus Erythematosus.Int J Mol Sci. 2023 19;24(10):8987. doi: 10.3390/ijms24108987.

12. Gajewska J., Ambroszkiewicz J., Weker H. et al. Relations between oxidized low-density lipoproteins and fat-soluble vitamin concentrations in obese children - preliminary study. Dev Period Med. 2017;21(3):266-271. doi: 10.34763/devperiodmed.20172103.266271.

13. Cicero A. F., Reggi A., Tartagni E. et al. Brisighella Heart Study Dietary determinants of oxidized-low-density lipoprotein antibodies in a sample of pharmacologically untreated non-smoker subjects: data from the Brisighella Heart Study. Adv Clin Exp Med. 2013;22(1):69-76.

14. Sanches L. B., da Silva I. T., Paz A. F. et al. Anti-oxLDL autoantibodies and their correlation with lipid profile and nutritional status in adolescents. J Pediatr (Rio J). 2008;84(3):258-263. doi: 10.2223/JPED.1805.

15. Tumova E., Sun W., Jones P. H. et al. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013:729515. doi: 10.1155/2013/729515.

16. Garrido-Sanchez L., Garcia-Pinilla J. M., Jimenez-Navarro M. et al. Reduced levels of anti-MDA LDL antibodies in patients with carbohydrate metabolism disorders. Clin Lab. 2011;57(11-12):901-907.